問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

未分科

List

16Cases

2021-06-01 - 2023-12-31

Phase I/II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2012-11-01 - 2018-01-31

Phase III

A Randomised, Double-blind, Parallel-group, Multicentre, Phase III Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEXTM) 500 mg with Anastrozole (ARIMIDEXTM) 1 mg as Hormonal Treatment for Postmenopausal Women with Hormone Receptor-Positive Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Been Treated With Any Hormonal Therapy (FALCON)

  • Condition/Disease

    Breast Cancer

  • Test Drug

    FASLODEX

Participate Sites
5Sites

Terminated5Sites

2020-11-20 - 2025-12-31

Phase I

A Phase 1b Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination with Other Anti-cancer Agents in Patients with Metastatic HER2-low Breast Cancer (DESTINY-Breast08)

  • Condition/Disease

    Metastatic HER2-low Breast Cancer

  • Test Drug

    Trastuzumab deruxtecan (ENHERTUR) Durvalumab (Imfinzi?) Capivasertib

Participate Sites
7Sites

Recruiting7Sites

2014-03-31 - 2022-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-05-31 - 2023-03-14

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Not yet recruiting2Sites

Recruiting2Sites

2012-11-01 - 2014-12-31

Phase III

A multicentre, randomised, phase III study of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and a taxane

  • Condition/Disease

    advanced breast cancer

  • Test Drug

    JAVLOR

Participate Sites
4Sites

Terminated3Sites

Study ended1Sites

1 2
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB